These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 15606031

  • 21. Polymorphic CYP2A6 and its clinical and toxicological significance.
    Rautio A.
    Pharmacogenomics J; 2003; 3(1):5-7. PubMed ID: 12629576
    [No Abstract] [Full Text] [Related]

  • 22. Metabolism and disposition kinetics of nicotine.
    Hukkanen J, Jacob P, Benowitz NL.
    Pharmacol Rev; 2005 Mar; 57(1):79-115. PubMed ID: 15734728
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6.
    Nakajima M, Itoh M, Yamanaka H, Fukami T, Tokudome S, Yamamoto Y, Yamamoto H, Yokoi T.
    J Clin Pharmacol; 2006 Mar; 46(3):337-44. PubMed ID: 16490810
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
    Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K.
    Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
    Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T.
    Br J Clin Pharmacol; 2002 Nov; 54(5):511-7. PubMed ID: 12445030
    [Abstract] [Full Text] [Related]

  • 31. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
    O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan-Davey E, Wong S, Hanley J, Tyndale RF.
    Tob Control; 2004 Dec; 13(4):422-8. PubMed ID: 15564629
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Metabolism and biochemical effects of nicotine for primary care providers.
    Metz CN, Gregersen PK, Malhotra AK.
    Med Clin North Am; 2004 Nov; 88(6):1399-413, ix. PubMed ID: 15464104
    [Abstract] [Full Text] [Related]

  • 34. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
    Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T.
    Eur J Pharm Sci; 2004 Aug; 22(5):419-25. PubMed ID: 15265511
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
    Swan GE, Benowitz NL, Lessov CN, Jacob P, Tyndale RF, Wilhelmsen K.
    Pharmacogenet Genomics; 2005 Feb; 15(2):115-25. PubMed ID: 15861035
    [Abstract] [Full Text] [Related]

  • 38. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
    Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T.
    Pharmacogenomics J; 2006 Feb; 6(6):401-12. PubMed ID: 16636685
    [Abstract] [Full Text] [Related]

  • 39. Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
    Kwon JT, Nakajima M, Chai S, Yom YK, Kim HK, Yamazaki H, Sohn DR, Yamamoto T, Kuroiwa Y, Yokoi T.
    Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.